For Africans, the data might have more tangible benefits. The continent's rich genetic diversity means that some drugs designed to treat Europeans do not work well in Africans. And genome-wide association studies designed to trace the genetic underpinnings of disease are difficult to execute in Africa because the arrays used to detect genetic variation were designed using mostly European sequences. As a result, researchers lack the tools to study important medical mysteries, such as why the Khoisan and some other African populations are particularly susceptible to tuberculosis . The Khoisan also lack a gene variant giving protection against malaria infection by Plasmodium vivax. This could reflect their lifestyle, Schuster says: with both water and cattle scarce, the Khoisan face little threat from malaria. But as agricultural communities encroach on the Khoisan habitat, or more Khoisan take up farming, the population may find itself increasingly vulnerable to infection.
Nevertheless, Tishkoff cautions against reading too much into the sequence data at this early stage. "You really need to have population-level information," she says. "If I see a variant in just one person, I don't know how prominent it's going to be in the rest of the population." To that end, Schuster and his team have used the sequence information to generate arrays containing more than 1.5 million markers that can be used to quickly assess genetic variation in large groups of people. They have already recruited hundreds of volunteers from different ethnic groups in Africa, and plan to begin using the arrays shortly .
Meanwhile, Tishkoff notes that the falling price and accelerating pace of sequencing mean that other African genomes are likely to be sequenced in the future. "We don't want to see any population being left out of this genomics revolution," she says.
